Private Advisory Group LLC Has $10.31 Million Stake in Novo Nordisk A/S $NVO

Private Advisory Group LLC boosted its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 3,357.7% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 185,816 shares of the company’s stock after acquiring an additional 180,442 shares during the quarter. Private Advisory Group LLC’s holdings in Novo Nordisk A/S were worth $10,311,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. True Wealth Design LLC lifted its holdings in Novo Nordisk A/S by 209.8% during the 3rd quarter. True Wealth Design LLC now owns 443 shares of the company’s stock valued at $25,000 after purchasing an additional 300 shares during the last quarter. NewSquare Capital LLC grew its stake in Novo Nordisk A/S by 174.1% during the second quarter. NewSquare Capital LLC now owns 444 shares of the company’s stock worth $31,000 after buying an additional 282 shares during the last quarter. Guerra Advisors Inc acquired a new stake in shares of Novo Nordisk A/S during the third quarter worth approximately $25,000. Strengthening Families & Communities LLC bought a new position in shares of Novo Nordisk A/S in the third quarter valued at approximately $30,000. Finally, Steigerwald Gordon & Koch Inc. acquired a new position in shares of Novo Nordisk A/S in the 3rd quarter worth approximately $39,000. 11.54% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on NVO shares. Jefferies Financial Group upgraded Novo Nordisk A/S from an “underperform” rating to a “hold” rating in a research report on Thursday, February 12th. BMO Capital Markets reiterated a “market perform” rating on shares of Novo Nordisk A/S in a research report on Thursday, February 5th. Morgan Stanley reissued an “underweight” rating and set a $42.00 price objective on shares of Novo Nordisk A/S in a report on Wednesday, December 3rd. Zacks Research cut shares of Novo Nordisk A/S from a “hold” rating to a “strong sell” rating in a research report on Monday, February 9th. Finally, Citigroup initiated coverage on shares of Novo Nordisk A/S in a research report on Tuesday, January 27th. They set a “neutral” rating on the stock. Seven investment analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $56.07.

Novo Nordisk A/S Stock Down 2.1%

Shares of NYSE:NVO opened at $47.43 on Monday. The company has a debt-to-equity ratio of 0.61, a current ratio of 0.80 and a quick ratio of 0.57. The stock has a market cap of $211.77 billion, a price-to-earnings ratio of 13.67 and a beta of 0.67. The company has a 50 day moving average of $53.77 and a 200-day moving average of $53.30. Novo Nordisk A/S has a one year low of $43.08 and a one year high of $93.80.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings data on Tuesday, February 3rd. The company reported $1.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.90 by $0.11. The firm had revenue of $12.43 billion for the quarter, compared to analysts’ expectations of $11.97 billion. Novo Nordisk A/S had a net margin of 33.03% and a return on equity of 68.91%. On average, sell-side analysts forecast that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Announces Dividend

The business also recently disclosed a dividend, which will be paid on Wednesday, April 8th. Investors of record on Monday, March 30th will be paid a dividend of $1.2751 per share. The ex-dividend date of this dividend is Monday, March 30th. This represents a dividend yield of 541.0%. Novo Nordisk A/S’s payout ratio is 23.63%.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.